Now Available: Revance and Teoxane’s RHA Dynamic Volume

Revance and Teoxane’s RHA Dynamic Volume, formerly RHA 4 Mepi, is now available.

Now US Food and Drug Administration (FDA)-approved for cheek augmentation and/or age-related midface contour deficiencies, RHA Dynamic Volume is designed to adapt to facial movement while delivering natural-looking results that last up to one year.

Providers can tailor treatments using Teoxane’s ATP approach (Anatomy, Assessment & Aging, Technique, Product) alongside the Teoxane MLT Multilayering Technique, allowing for balanced restoration of midface volume and facial harmony without overcorrection.

In clinical studies, approximately 98% of patients reported natural-looking results in the midface at two months, while more than 94% reported natural-feeling results at rest and in motion at one year. In clinical trials, RHA Dynamic Volume demonstrated a favorable safety profile, with no late-onset or serious treatment-related adverse events, and no events deemed to be granulomas or delayed inflammatory responses.

“RHA Dynamic Volume is an innovation for patients experiencing volume loss due to weight changes or aging in the midface, delivering results that are beautiful at rest and in motion,” says Jody Comstock, MD, a Dermatologist in Casas Adobes, AZ, in a news release. “It’s a versatile option that allows me to tailor treatments to each patient’s unique needs.”